Can infarct size be limited in patients with acute myocardial infarction?
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000188:drug therapy; D004285:Dogs; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy; D007328:Insulin / Q000627:therapeutic use; D007423:Intra-Aortic Balloon Pumping; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D009336:Necrosis; D005996:Nitroglycerin / Q000627:therapeutic use; D010100:Oxygen / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects; D011188:Potassium / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000893:Anti-Inflammatory Agents; D002316:Cardiotonic Agents; D005343:Fibrinolytic Agents; D007328:Insulin; D014665:Vasodilator Agents; C030396:glucose-insulin-potassium cardioplegic solution; D006821:Hyaluronoglucosaminidase; D005996:Nitroglycerin; D005947:Glucose; D011188:Potassium; D010100:Oxygen